A randomized multicenter study evaluating Xolair persistence of response after long-term therapy

2016219 citationsJournal Articlehybrid Open Access

Authors

Dennis K. Ledford · James A. Haley Veterans' Hospital

William W. Busse · University of Wisconsin–Madison

Benjamin Trzaskoma

Theodore A. Omachi

Karin Rosén

Bradley E. Chipps · Capital Allergy and Respiratory Disease Center

Allan T. Luskin · Dean Health Systems

Paul G. Solari

Abstract

Continuation of omalizumab after long-term treatment results in continued benefit, as evidenced by improved symptom control and reduced exacerbation risk.

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research Allergic Rhinitis and Sensitization

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Allergy and Clinical Immunology

Volume 140, Issue 1, pp. 162-169.e2

DOI: 10.1016/j.jaci.2016.08.054

Field-Weighted Citation Impact: 13.43